COLL Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 21.93%. Collegium Pharmaceutical's return on equity of 19.31% beat Bristol-Myers Squibb's return on equity of 32.01%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 41.36%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.10 which suggests that it could grow by 14.77%. Given that Collegium Pharmaceutical has higher upside potential than Bristol-Myers Squibb, analysts believe Collegium Pharmaceutical is more attractive than Bristol-Myers Squibb.

Collegium Pharmaceutical has a beta of 0.635, which suggesting that the stock is 36.534% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.378, suggesting its less volatile than the S&P 500 by 62.23%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.91% to investors and pays a quarterly dividend of $0.62 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Collegium Pharmaceutical's net income of $2.4M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.92x while Bristol-Myers Squibb's PE ratio is 18.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.69x versus 2.12x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 13.07%. Collegium Pharmaceutical's return on equity of 19.31% beat Corcept Therapeutics's return on equity of 21.3%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 41.36%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 97.33%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.635, which suggesting that the stock is 36.534% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.186, suggesting its less volatile than the S&P 500 by 81.38%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Corcept Therapeutics quarterly revenues of $157.2M. Collegium Pharmaceutical's net income of $2.4M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.92x while Corcept Therapeutics's PE ratio is 60.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.69x versus 11.86x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of -7.89%. Collegium Pharmaceutical's return on equity of 19.31% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 41.36%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 21.14%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.635, which suggesting that the stock is 36.534% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.985%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Collegium Pharmaceutical's net income of $2.4M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.92x while Supernus Pharmaceuticals's PE ratio is 28.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.69x versus 2.69x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 28.42%. Collegium Pharmaceutical's return on equity of 19.31% beat Zoetis's return on equity of 51.03%.

Collegium Pharmaceutical has a consensus price target of $41.25, signalling upside risk potential of 41.36%. On the other hand Zoetis has an analysts' consensus of $195.37 which suggests that it could grow by 18.89%. Given that Collegium Pharmaceutical has higher upside potential than Zoetis, analysts believe Collegium Pharmaceutical is more attractive than Zoetis.

Collegium Pharmaceutical has a beta of 0.635, which suggesting that the stock is 36.534% less volatile than S&P 500. In comparison Zoetis has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.913%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.13% to investors and pays a quarterly dividend of $0.50 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are smaller than Zoetis quarterly revenues of $2.2B. Collegium Pharmaceutical's net income of $2.4M is lower than Zoetis's net income of $631M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.92x while Zoetis's PE ratio is 29.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.69x versus 8.00x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.